PT  - JOURNAL ARTICLE
AU  - Catharina Busch
AU  - Matus Rehak
AU  - Chintan Sarvariya
AU  - Dinah Zur
AU  - Matias Iglicki
AU  - Luiz H Lima
AU  - Alessandro Invernizzi
AU  - Francesco Viola
AU  - Kushal Agrawal
AU  - Suthasinee Sinawat
AU  - Aude Couturier
AU  - Aanchal Mehta
AU  - Rakesh Juneja
AU  - Hardik Jain
AU  - Aniruddha Kishandutt Agarwal
AU  - Neha Goel
AU  - Manish Nagpal
AU  - Vishali Gupta
AU  - Alay Banker
AU  - Anat Loewenstein
AU  - Mali Okada
AU  - Ali Osman Saatci
AU  - Ahmad M Mansour
AU  - Jay Chhablani
TI  - Long-term visual outcome and its predictors in macular oedema secondary to retinal vein occlusion treated with dexamethasone implant
AID  - 10.1136/bjophthalmol-2017-311805
DP  - 2018 Jun 11
TA  - British Journal of Ophthalmology
PG  - bjophthalmol-2017-311805
4099  - http://bjo.bmj.com/content/early/2018/06/11/bjophthalmol-2017-311805.short
4100  - http://bjo.bmj.com/content/early/2018/06/11/bjophthalmol-2017-311805.full
AB  - Background To evaluate the functional long-term outcome in patients with macular oedema (MO) secondary to central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) treated with dexamethasone implant (DEX implant) and to identify its clinical predictors.Methods A 24-month, retrospective, multinational, real-world study. Chart review of patients with either naïve or recurrent MO secondary to CRVO/BRVO treated with DEX implant, including best-corrected visual acuity (BCVA), central subfield thickness (CST), demographic baseline characteristics and details of any additional treatment during follow-up.Results A total of 155 eyes (65 CRVO, 90 BRVO) from 155 patients were included. At 24 months, mean BCVA did not change significantly in CRVO (−2.1±24.5 letters, p=0.96) and BRVO patients (1.3±27.0 letters, p=0.07). A worse baseline BCVA (p<0.001), visual acuity (VA) gain ≥5 letters at 2 months (p=0.006) and no need for adjunctive intravitreal therapy after first DEX implant (p=0.001) were associated with a better final BCVA gain. Treatment-naïve patients (p=0.006, OR: 0.25, 95% CI 0.11 to 0.57) and those with a baseline CST≤400 µm (p=0.02, OR: 0.25, 95% CI 0.10 to 0.63) were identified as being less likely to need additional intravitreal therapy.Conclusion Clinical baseline characteristics and the early treatment response were identified as possible predictors for long-term outcome and the need of adjunctive intravitreal therapy in MO secondary to BRVO/CRVO treated by DEX implant.